Technical Analysis for 0WA2 - Cellectis S.A.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Doji - Bearish? | Reversal | 0.00% | |
Slingshot Bearish | Bearish Swing Setup | 1.67% | |
Gapped Up | Strength | 1.67% | |
Oversold Stochastic | Weakness | 1.67% | |
180 Bearish Setup | Bearish Swing Setup | 10.26% | |
Narrow Range Bar | Range Contraction | 10.26% | |
Gapped Down | Weakness | 10.26% | |
Oversold Stochastic | Weakness | 10.26% | |
New Uptrend | Bullish | 1.92% | |
Stochastic Buy Signal | Bullish | 1.92% |
Free Daily (Stock) Chart Reading
Cellectis S.A. Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Classification
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.6544 |
52 Week Low | 0.9205 |
Average Volume | 7,645 |
200-Day Moving Average | 2.04 |
50-Day Moving Average | 2.65 |
20-Day Moving Average | 2.50 |
10-Day Moving Average | 2.39 |
Average True Range | 0.15 |
RSI (14) | 51.22 |
ADX | 22.51 |
+DI | 28.11 |
-DI | 19.26 |
Chandelier Exit (Long, 3 ATRs) | 2.41 |
Chandelier Exit (Short, 3 ATRs) | 2.70 |
Upper Bollinger Bands | 2.79 |
Lower Bollinger Band | 2.21 |
Percent B (%b) | 0.49 |
BandWidth | 22.95 |
MACD Line | -0.08 |
MACD Signal Line | -0.08 |
MACD Histogram | -0.0052 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.78 | ||||
Resistance 3 (R3) | 2.75 | 2.62 | 2.73 | ||
Resistance 2 (R2) | 2.62 | 2.55 | 2.64 | 2.72 | |
Resistance 1 (R1) | 2.56 | 2.50 | 2.59 | 2.59 | 2.70 |
Pivot Point | 2.43 | 2.43 | 2.45 | 2.45 | 2.43 |
Support 1 (S1) | 2.37 | 2.36 | 2.40 | 2.40 | 2.29 |
Support 2 (S2) | 2.24 | 2.31 | 2.26 | 2.27 | |
Support 3 (S3) | 2.18 | 2.24 | 2.26 | ||
Support 4 (S4) | 2.21 |